Matthew D. Wilkerson, Jason M. Schallheim, D. Neil Hayes, Patrick J

Slides:

Advertisements

Similar presentations

Measurement of Relative Copy Number of CDKN2A/ARF and CDKN2B in Bladder Cancer by Real-Time Quantitative PCR and Multiplex Ligation-Dependent Probe Amplification.

Advertisements

Telomerase Activity and Expression of Telomerase RNA Component and Telomerase Catalytic Subunit Gene in Cervical Cancer Kenji Nakano, Elizabeth Watney,

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors Neal I. Lindeman, Philip T. Cagle, Mary Beth.

CyclinD1/CyclinD3 Ratio by Real-Time PCR Improves Specificity for the Diagnosis of Mantle Cell Lymphoma Carol D. Jones, Katherine H. Darnell, Roger A.

Design and Multiseries Validation of a Web-Based Gene Expression Assay for Predicting Breast Cancer Recurrence and Patient Survival Ryan K. Van Laar The.

Prediction of Lung Cancer Histological Types by RT-qPCR Gene Expression in FFPE Specimens Matthew D. Wilkerson, Jason M. Schallheim, D. Neil Hayes, Patrick.

Oligonucleotide PIK3CA/Chromosome 3 Dual in Situ Hybridization Automated Assay with Improved Signals, One-Hour Hybridization, and No Use of Blocking DNA

Sensitivity Analysis of the MGMT-STP27 Model and Impact of Genetic and Epigenetic Context to Predict the MGMT Methylation Status in Gliomas and Other.

Genes with Bimodal Expression Are Robust Diagnostic Targets that Define Distinct Subtypes of Epithelial Ovarian Cancer with Different Overall Survival

Statistical Considerations for Immunohistochemistry Panel Development after Gene Expression Profiling of Human Cancers Rebecca A. Betensky, Catherine.

Sensitivity Analysis of the MGMT-STP27 Model and Impact of Genetic and Epigenetic Context to Predict the MGMT Methylation Status in Gliomas and Other.

Carol Beadling, Tanaya L. Neff, Michael C

Lunx Is a Superior Molecular Marker for Detection of Non-Small Lung Cell Cancer in Peripheral Blood Michael Mitas, Loretta Hoover, Gerard Silvestri,

Assessing Copy Number Alterations in Targeted, Amplicon-Based Next-Generation Sequencing Data Catherine Grasso, Timothy Butler, Katherine Rhodes, Michael.

Laboratory Guidelines for Detection, Interpretation, and Reporting of Maternal Cell Contamination in Prenatal Analyses Narasimhan Nagan, Nicole E. Faulkner,

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors Neal I. Lindeman, Philip T. Cagle, Mary.

Mark G. Erlander, Xiao-Jun Ma, Nicole C

Michael D. Onken, Lori A. Worley, Rosa M. Dávila, Devron H. Char, J

Molecular Genetics of Pediatric Soft Tissue Tumors

Development and Validation of a Preanalytic Procedure for Performing the cobas HPV Test in SurePath Preservative Fluid Mark D. Krevolin, David Hardy,

Oligonucleotide PIK3CA/Chromosome 3 Dual in Situ Hybridization Automated Assay with Improved Signals, One-Hour Hybridization, and No Use of Blocking DNA

Joanna Wang, Chetan Bettegowda The Journal of Molecular Diagnostics

Increased Sensitivity of the Roche COBAS AMPLICOR HCV Test, Version 2

Maxim B. Freidin, Neesa Bhudia, Eric Lim, Andrew G

Design and Multiseries Validation of a Web-Based Gene Expression Assay for Predicting Breast Cancer Recurrence and Patient Survival Ryan K. Van Laar

Christopher R. Cabanski, Vincent Magrini, Malachi Griffith, Obi L

An Accurate, Clinically Feasible Multi-Gene Expression Assay for Predicting Metastasis in Uveal Melanoma Michael D. Onken, Lori A. Worley, Meghan D.

CRISPR/Cas9 Technology–Based Xenograft Tumors as Candidate Reference Materials for Multiple EML4-ALK Rearrangements Testing Rongxue Peng, Rui Zhang,

ALK Status Testing in Non–Small Cell Lung Carcinoma

Molecular Classification of MYC-Driven B-Cell Lymphomas by Targeted Gene Expression Profiling of Fixed Biopsy Specimens Christopher D. Carey, Daniel.

The History and Impact of Molecular Coding Changes on Coverage and Reimbursement of Molecular Diagnostic Tests Susan J. Hsiao, Mahesh M. Mansukhani,

Getting Things Backwards to Prevent Primer Dimers

Patrick R. Murray The Journal of Molecular Diagnostics

William L. Gerald, M.D., Ph.D, 1954–2008

Yuqiu Jiang, Graham Casey, Ian C

QuantiGene Plex Represents a Promising Diagnostic Tool for Cell-of-Origin Subtyping of Diffuse Large B-Cell Lymphoma John S. Hall, Suzanne Usher, Richard.

Hillary S. Sloane, James P. Landers, Kimberly A. Kelly

Utility of NIST Whole-Genome Reference Materials for the Technical Validation of a Multigene Next-Generation Sequencing Test Bennett O.V. Shum, Ilya.

Christine Formisano-Tréziny, Marina de San Feliciano, Jean Gabert

Olivier Gruselle, Thierry Coche, Jamila Louahed

Comparison of KRAS Mutation Analysis and FISH for Detecting Pancreatobiliary Tract Cancer in Cytology Specimens Collected During Endoscopic Retrograde.

BRAF Mutation Testing in Solid Tumors

Skin Biopsy Is a Practical Approach for the Clinical Diagnosis and Molecular Genetic Analysis of X-Linked Alport's Syndrome Fang Wang, Dan Zhao, Jie.

The Molecular Pathology of Primary Immunodeficiencies

Amplification Patterns of Three Genomic Regions Predict Distant Recurrence in Breast Carcinoma Lisa M. Davis, Cole Harris, Lei Tang, Patti Doherty, Peter.

Validation of a Gene Expression Test for Mesothelioma Prognosis in Formalin-Fixed Paraffin-Embedded Tissues Assunta De Rienzo, Robert W. Cook, Jeff Wilkinson,

Multi-Institutional FASTQ File Exchange as a Means of Proficiency Testing for Next- Generation Sequencing Bioinformatics and Variant Interpretation Kurtis.

Analytical Performance of a 15-Gene Prognostic Assay for Early-Stage Non–Small-Cell Lung Carcinoma Using RNA-Stabilized Tissue Shuguang Huang, Nicholas.

Implications for Powering Biomarker Discovery Studies

Sarah E. Kerr, Cheryl B. Thomas, Stephen N. Thibodeau, Matthew J

Multiplexed Methylation Profiles of Tumor Suppressor Genes in Bladder Cancer Maria José Cabello, Laura Grau, Noreli Franco, Esteban Orenes, Miguel Alvarez,

Quality Assurance for Duchenne and Becker Muscular Dystrophy Genetic Testing Lisa Kalman, Jay Leonard, Norman Gerry, Jack Tarleton, Christina Bridges,

Retrospective Comparison of Nucleic Acid Sequence–Based Amplification, Real-Time PCR, and Galactomannan Test for Diagnosis of Invasive Aspergillosis

Genomic Technologies and the New Era of Genomic Medicine

Molecular Monitoring of Chronic Myeloid Leukemia

Avoiding Pitfalls in Molecular Genetic Testing

Intratumoral Heterogeneity of MicroRNA Expression in Breast Cancer

Oligonucleotide PIK3CA/Chromosome 3 Dual in Situ Hybridization Automated Assay with Improved Signals, One-Hour Hybridization, and No Use of Blocking DNA

Mutations in the Kinase Domain of the HER2/ERBB2 Gene Identified in a Wide Variety of Human Cancers Wenhsiang Wen, Wangjuh (Sting) Chen, Nick Xiao, Ryan.

MiRNA Profiling Identifies Candidate miRNAs for Bladder Cancer Diagnosis and Clinical Outcome Nadine Ratert, Hellmuth-Alexander Meyer, Monika Jung, Poline.

A Platform for Rapid Detection of Multiple Oncogenic Mutations With Relevance to Targeted Therapy in Non–Small-Cell Lung Cancer Zengliu Su, Dora Dias-Santagata,

Statistical Treatment of Fluorescence in Situ Hybridization Validation Data to Generate Normal Reference Ranges Using Excel Functions Allison L. Ciolino,

Custom Design of a GeXP Multiplexed Assay Used to Assess Expression Profiles of Inflammatory Gene Targets in Normal Colon, Polyp, and Tumor Tissue Janice.

Validation and Reproducibility of a Microarray-Based Gene Expression Test for Tumor Identification in Formalin-Fixed, Paraffin-Embedded Specimens Raji.

Development and Validation of a Computational Method for Assessment of Missense Variants in Hypertrophic Cardiomyopathy Daniel M. Jordan, Adam Kiezun,

Improved Detection of the KIT D816V Mutation in Patients with Systemic Mastocytosis Using a Quantitative and Highly Sensitive Real-Time qPCR Assay Thomas.

Efficient Identification of miRNAs for Classification of Tumor Origin

Clinical Experience with the Cervista HPV HR Assay

Monique A. Johnson, Marvin J. Yoshitomi, C. Sue Richards

The History and Impact of Molecular Coding Changes on Coverage and Reimbursement of Molecular Diagnostic Tests Susan J. Hsiao, Mahesh M. Mansukhani,

Presentation transcript:

Prediction of Lung Cancer Histological Types by RT-qPCR Gene Expression in FFPE Specimens Matthew D. Wilkerson, Jason M. Schallheim, D. Neil Hayes, Patrick J. Roberts, Roy R.L. Bastien, Michael Mullins, Xiaoying Yin, C. Ryan Miller, Leigh B. Thorne, Katherine B. Geiersbach, Kenneth L. Muldrew, William K. Funkhouser, Cheng Fan, Michele C. Hayward, Steven Bayer, Charles M. Perou, Philip S. Bernard The Journal of Molecular Diagnostics Volume 15, Issue 4, Pages 485-497 (July 2013) DOI: 10.1016/j.jmoldx.2013.03.007 Copyright © 2013 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions

Figure 1 HEP performance. A: Performance of the cross-validation iterations (n = 1000). Prediction confidence and stromal score tertiles were assigned in each cross-validation iteration. Tertile accuracies over all the iterations are displayed. Data are shown as means (95% CIs). B: Total training performance for the final predictor applied to the predictor development tumor set. Each column represents one tumor specimen. NA, not assessed. The Journal of Molecular Diagnostics 2013 15, 485-497DOI: (10.1016/j.jmoldx.2013.03.007) Copyright © 2013 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions

Figure 2 HEP compared with pathologist diagnosis. A: Single-block independent validation set results. Columns represent the same tumor specimen. Pathologist diagnoses of these same specimens are indicated by the bar graph in which the height of each colored bar represents the portion that the specimen was diagnosed as having a histology of corresponding color. In one case (marked with an asterisk), all the study pathologists and the HEP were in agreement but in disagreement with the clinical diagnosis. B: Dual-block independent validation set results. Tumor replicate specimens (blocks) are indicated by black vertical bars. The Journal of Molecular Diagnostics 2013 15, 485-497DOI: (10.1016/j.jmoldx.2013.03.007) Copyright © 2013 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions

Figure 3 Prediction in specimens with low tumor content. The results for the low tumor content independent validation set are displayed. Each column represents one tumor specimen. The Journal of Molecular Diagnostics 2013 15, 485-497DOI: (10.1016/j.jmoldx.2013.03.007) Copyright © 2013 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions